(2-amino-5-chlorophenyl)(phenyl)methanone oxime, often referred to as **AMCPO**, is a chemical compound that has attracted attention in research due to its potential applications in various fields.
**Structure and Properties:**
* **Molecular Formula:** C13H11ClN2O
* **Molecular Weight:** 262.7 g/mol
* **Appearance:** White to off-white solid
* **Solubility:** Soluble in organic solvents like ethanol and chloroform
**Research Significance:**
AMCPO has garnered research interest for several reasons:
1. **Antimicrobial Activity:** Studies have shown that AMCPO possesses significant antimicrobial activity against a range of bacteria, including **Staphylococcus aureus**, **Escherichia coli**, and **Pseudomonas aeruginosa**. This activity is attributed to its ability to interfere with the growth and replication of bacterial cells.
2. **Anti-inflammatory Properties:** AMCPO has also been investigated for its potential anti-inflammatory effects. Research suggests it may inhibit the production of pro-inflammatory mediators, potentially contributing to the reduction of inflammation.
3. **Antioxidant Activity:** Studies indicate that AMCPO possesses antioxidant properties. It can scavenge free radicals, protecting cells from oxidative stress, which is linked to various health issues.
4. **Drug Delivery:** AMCPO has been explored as a potential carrier for drug delivery. Its chemical structure allows it to bind to certain drugs, facilitating their transport to target sites within the body.
5. **Other Applications:** Research is ongoing to explore other potential applications of AMCPO, including its use in organic synthesis and material science.
**Current Research:**
Research into AMCPO is still ongoing, with researchers exploring its various biological activities, potential applications in drug development, and its impact on specific cellular processes. The aim is to fully understand its mechanism of action and optimize its properties for specific therapeutic or industrial uses.
**Note:** It's crucial to note that while research is promising, more studies are needed to fully understand the safety and efficacy of AMCPO for human use.
ID Source | ID |
---|---|
PubMed CID | 5398630 |
CHEMBL ID | 3208177 |
CHEBI ID | 190626 |
Synonym |
---|
4-chloro-2-[(hydroxyimino)(phenyl)methyl]aniline |
smr000034150 |
MLS000078203 |
SR-01000414316-2 |
4-chloro-2-[(e)-(hydroxyimino)(phenyl)methyl]aniline |
STK806178 |
AKOS000279605 |
HMS551D11 |
(2-amino-5-chlorophenyl)(phenyl)methanone oxime |
(ne)-n-[(2-amino-5-chlorophenyl)-phenylmethylidene]hydroxylamine |
CHEBI:190626 |
(e)-n-[(2-amino-5-chlorophenyl)-phenylmethylidene]hydroxylamine |
benzophenone, 2-amino-5-chloro-, oxime |
A812573 |
CCG-48409 |
(2-amino-5-chloro-phenyl)-phenyl-methanone oxime |
(e)-(2-amino-5-chlorophenyl)(phenyl)methanone oxime # |
GCAVNCINXJNLED-DTQAZKPQSA-N |
W-109174 |
CHEMBL3208177 |
SR-01000414316-1 |
sr-01000414316 |
2-amino-5-chlorbenzophenonoxim |
2-amino-5-chlorobenzophenone i+/--oxime-, (z)- |
methanone, (2-amino-5-chlorophenyl)phenyl-, oxime, (e)- |
A4AZJ6W4EQ |
methanone, (2-amino-5-chlorophenyl)phenyl-, oxime, (1e)- |
anti-2-amino-5-chlorobenzophenone oxime |
2-amino-5-chlorobenzophenone oxime, (e)- |
benzophenone, 2-amino-5-chloro-, oxime, (e)- |
DTXSID901230398 |
(1e)-(2-amino-5-chlorophenyl)phenylmethanone oxime |
Class | Description |
---|---|
diarylmethane | Any compound containing two aryl groups connected by a single C atom. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
glp-1 receptor, partial | Homo sapiens (human) | Potency | 11.2202 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 14.1254 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 11.2202 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 50.1187 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
FAD-linked sulfhydryl oxidase ALR | Homo sapiens (human) | AC50 | 22.7870 | 0.0050 | 3.2126 | 22.7870 | AID493248 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |